FindTrial
Sign In

The safety and efficacy of Terezumab combined with Docetaxel and Cisplatin in treating patients with resectable esophageal squamous cell carcinoma

The safety and efficacy of Terezumab combined with Docetaxel and Cisplatin in treating patients with resectable esophageal squamous cell carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200060972
Enrollment
Unknown
Registered
2022-06-14
Start date
2022-06-01
Completion date
Unknown
Last updated
2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

local advanced esophageal squamous cell carcinoma

Interventions

chemotherapy plus immunotherapy:Terezumab combined with Docetaxel and Cisplatin

Sponsors

Department of thoracic surgery, Army medical center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.= 18 years old 2.resectable ESCC in stage cT1-2N + M0 and cT3NanyM0 (AJCC version 8) 3.ECOG: 0 or 1; 4.R0 resection

Exclusion criteria

Exclusion criteria: 1.concerrent with other malignant tumors; 2.history of receiving treatment of chemotherapy, chemoradiotherapy, PD-1, PD-L1 or PD-L2; 3.can not tolerate the chemotherapy, chemoradiotherapy or surgery

Design outcomes

Primary

MeasureTime frame
overall survival;—

Secondary

MeasureTime frame
pathological complete response;major pathological response;R0 resection rate;disease free survival;—

Countries

China

Contacts

Public ContactWei Guo

Department of thoracic surgery, Army medical center

gyguowei@hotmail.com13527323568

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026